ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreement
2024年5月20日 - 5:43PM
ビジネスワイヤ(英語)
License agreement provides IRBM access to
CRISPR gene editing technology to be applied across its drug
discovery services offering
ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and
IRBM, a leader in the field of drug discovery, today announced a
non-exclusive CRISPR/Cas9 license agreement. The agreement grants
IRBM access to ERS’ CRISPR/Cas9 patent portfolio.
IRBM is a drug discovery CRO with expertise ranging from target
validation and hit finding to preclinical candidate nomination
across various therapeutic areas, including oncology, infectious
diseases, and neuroscience. The company has contributed to the
discovery and development of four marketed therapeutics for HIV,
HCV, ovarian cancer, and cutaneous T-cell lymphoma.
Carlo Toniatti, MD, PhD, CSO, IRBM, said: “We are
committed to delivering high quality drugs by leveraging our broad
range of expertise and capabilities across the entire preclinical
drug discovery continuum. With the integration of CRISPR/Cas9 gene
editing technology we are increasing our capability to identify and
validate potential drug targets, to generate more predictive
pre-clinical models and to elucidate the mechanisms of action of
novel therapeutics.”
John E Milad, CEO, ERS Genomics, commented: “We are
committed to supporting cutting-edge research and expanding the
horizons of medical innovation by providing companies such as IRBM
with the ability to take advantage of CRISPR/Cas9 technology. We
look forward to seeing the innovative ways in which our gene
editing technology will be utilised in various stages of drug
discovery, providing candidates for a wide range of therapeutic
areas.”
ERS Genomics provides licensing to CRISPR/Cas9 technology for
companies interested in pursuing its use in their commercial
programs. Comprising 100+ patents globally, ERS’ portfolio
encompasses CRISPR/Cas9 usage in all cells, including eukaryotic
and prokaryotic cells such as mammalian cells, bacteria, archaea,
yeasts, algae, and insects. ERS Genomics licenses these patents via
its direct license from Emmanuelle Charpentier and now has nearly
150 licenses in place worldwide.
Financial details of the agreement are not disclosed.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240520044085/en/
Dr Ben Rutter Zyme Communications Tel: +44(0)7920 770 935 Email:
ben.rutter@zymecommunications.com